Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

Effekt og sikkerhet av intravesikal TARA-002 sammenlignet med forskerens valg av intravesikal kjemoterapi hos deltakere med BCG-naivt høygradig ikke-muskelinvasiv blærekreft (ADVANCED-3)

5. oktober 2026 oppdatert av: Protara Therapeutics

En fase 3, randomisert studie for å evaluere effektiviteten og sikkerheten til intravesikal TARA-002 sammenlignet med forskerens valg av intravesikal kjemoterapi hos deltakere med BCG-naivt høggradig ikke-muskelinvasiv blærekreft

The goal of this clinical trial is to learn if TARA-002 can treat high-grade non-muscle invasive bladder cancer (NMIBC) in BCG-naïve adults 18 years of age or older.

The main questions it aims to answer are:

  • Can the study drug help participants with this type of cancer?
  • Is the study drug safe?
  • What are the side effects of the study drug?

Researchers will compare TARA-002 to chemotherapy to see if TARA-002 works to treat NMIBC.

Studieoversikt

Studietype

Intervensjonell

Registrering (Antatt)

284

Fase

  • Fase 3

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiekontakt

Studiesteder

    • Arizona
      • Queen Creek, Arizona, Forente stater, 85140
        • Rekruttering
        • East Valley Urology Center of Arizona
        • Ta kontakt med:
          • Use Central Contact
    • Arkansas
      • Little Rock, Arkansas, Forente stater, 72211
        • Rekruttering
        • Arkansas Urology
        • Ta kontakt med:
          • Use Central Contact
    • California
      • Bakersfield, California, Forente stater, 93301
        • Rekruttering
        • Michael Oefelein Clinical Trials
    • Georgia
      • Atlanta, Georgia, Forente stater, 30319
        • Rekruttering
        • Urology of Greater Atlanta - Sandy Springs
        • Ta kontakt med:
          • Use Central Contact
    • Missouri
      • St Louis, Missouri, Forente stater, 63110
        • Rekruttering
        • Renown Regional Medical Center
        • Ta kontakt med:
          • Use Central Contact
    • South Carolina
      • Myrtle Beach, South Carolina, Forente stater, 29572
        • Rekruttering
        • START - Carolinas
        • Ta kontakt med:
          • Use Central Contact
    • Texas
      • Arlington, Texas, Forente stater, 76017
        • Rekruttering
        • Urology Partners of North Texas
        • Ta kontakt med:
          • Use Central Contact
      • Austin, Texas, Forente stater, 78745
        • Rekruttering
        • Urology Austin, LLC
        • Ta kontakt med:
          • Use Central Contact
      • Houston, Texas, Forente stater, 77027
        • Rekruttering
        • Houston Metro Urology
        • Ta kontakt med:
          • Use Central Contact
      • Ivano-Frankivsk, Ukraina, 76018
        • Rekruttering
        • Arenia - Ivano-Frankivsk
        • Ta kontakt med:
          • Use Central Contact
      • Kapitanivka, Ukraina, 08111
        • Rekruttering
        • Arensia Kapitanivka - PPDS
        • Ta kontakt med:
          • Use Central Contact

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

18 år og eldre (Voksen, Eldre voksen)

Tar imot friske frivillige

Nei

Kjønn som er kvalifisert for studier

Alle

Beskrivelse

Inclusion Criteria:

  • Male or female participants 18 years of age or older at the time of signing informed consent
  • Participants who have voluntarily given written informed consent after the nature of the study has been explained according to applicable requirements prior to study entry
  • Central histologic confirmation of high-grade non-muscle invasive CIS (± Ta/T1) with active disease
  • Participants who are BCG naive, or participants who are BCG exposed and have not received intravesical BCG for at least 24 months prior to the most recent CIS diagnosis, or participants who received ≤2 doses of BCG within the 24 months prior to the most recent CIS diagnosis

Exclusion Criteria:

  • Penicillin allergy (participants with a questionable history of allergy to penicillin will undergo penicillin blood allergy testing via central laboratory
  • Central confirmed variant histology
  • Concomitant prostatic or upper tract urothelial involvement per Investigator's assessment
  • Nodal and metastatic disease are excluded if they existed at any time (whether present or in the past)
  • Any history of ≥ T2 bladder cancer that existed at any point in time in the participant's history

For more information on eligibility criteria, please contact the Sponsor.

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Primært formål: Behandling
  • Tildeling: Randomisert
  • Intervensjonsmodell: Parallell tildeling
  • Masking: Ingen (Open Label)

Våpen og intervensjoner

Deltakergruppe / Arm
Intervensjon / Behandling
Eksperimentell: TARA-002 (Arm A)

Participants will receive 6 weekly instillations of TARA-002. Participants confirmed to have a CR at Week 12 will enter the maintenance treatment period and will receive 3 additional weekly instillations of TARA-002 every 3 months up to Month 19, and then 3 weekly doses at Month 25. Participants who are eligible for reinduction at Week 12 will receive 6 additional weekly instillations of TARA-002. Participants who undergo reinduction and are confirmed to have a CR at Week 24 will enter the maintenance regimen treatment period and will receive 3 weekly instillations of TARA-002 every 3 months up to Month 19, and then 3 weekly doses at Month 25.

Aktiv komparator: Forskerens valg av intravesikal kjemoterapi

Participants will receive 6 weekly instillations of Investigator's choice of intravesical chemotherapy. Participants confirmed to have a CR at Week 12 will enter the maintenance regimen treatment period and will receive one intravesical instillation of Investigator's choice of intravesical chemotherapy every 1 month up to Month 25.

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Incidence of high-grade complete response
Tidsramme: Month 6

Incidence of high-grade complete response of intravesical TARA-002 compared to Investigator's choice of intravesical chemotherapy determined by cystoscopy, urine cytology, and bladder biopsy (if applicable)

Month 6

Sekundære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Duration of high-grade complete response
Tidsramme: Up to Month 60

Duration of high-grade complete response of intravesical TARA-002 compared to Investigator's choice of intravesical chemotherapy

Up to Month 60
Treatment emergent adverse events
Tidsramme: Up to Month 60

Incidence and severity of treatment emergent adverse events (TEAEs) of intravesical TARA-002 compared to Investigator's choice of intravesical chemotherapy

Up to Month 60
Treatment emergent serious adverse events
Tidsramme: Up to Month 60

Incidence and severity of treatment emergent serious adverse events (TESAEs) of intravesical TARA-002 compared to Investigator's choice of intravesical chemotherapy

Up to Month 60
High-grade complete response rate
Tidsramme: At Months 3, 9, 12, 15, 18, 21, 24, 27, 30, 36, 42, 48, 54, and 60

High-grade complete response rate of intravesical TARA-002 compared to Investigator's choice of intravesical chemotherapy determined by cystoscopy, urine cytology, and bladder biopsy (if applicable)

At Months 3, 9, 12, 15, 18, 21, 24, 27, 30, 36, 42, 48, 54, and 60
High-grade complete response rate (CIS only)
Tidsramme: Month 6

High-grade complete response rate of intravesical TARA-002 compared to Investigator's choice of intravesical chemotherapy determined by cystoscopy, urine cytology, and bladder biopsy (if applicable) in sub-group of participants with CIS only

Month 6
Event-free survival
Tidsramme: Up to Month 60

Event-free survival (EFS) of intravesical TARA-002 compared to Investigator's choice of intravesical chemotherapy

Up to Month 60
Recurrence-free survival
Tidsramme: Up to Month 60

Recurrence-free survival (RFS) of intravesical TARA-002 compared to Investigator's choice of intravesical chemotherapy

Up to Month 60
Progression-free survival
Tidsramme: Up to Month 60

Progression-free survival (PFS) of intravesical TARA-002 compared to Investigator's choice of intravesical chemotherapy

Up to Month 60
Disease-specific progression-free survival
Tidsramme: Up ro Month 60

Disease-specific progression-free survival (DSPFS) of intravesical TARA-002 compared to Investigator's choice of intravesical chemotherapy

Up ro Month 60
Overall survival
Tidsramme: Up to Month 60

Overall survival (OS) of intravesical TARA-002 compared to Investigator's choice of intravesical chemotherapy

Up to Month 60
Disease-specific survival
Tidsramme: Up to Month 60

Disease-specific survival (DSS) of intravesical TARA-002 compared to Investigator's choice of intravesical chemotherapy

Up to Month 60
Time to cystectomy
Tidsramme: Up to Month 60

Time to cystectomy of intravesical TARA-002 compared to Investigator's choice of intravesical chemotherapy

Up to Month 60
Time to recurrence delayed cystectomy
Tidsramme: Up to Month 60

Time to recurrence delayed cystectomy of intravesical TARA-002 compared to Investigator's choice of intravesical chemotherapy

Up to Month 60
Time to progression
Tidsramme: Up to Month 60

Time to progression of intravesical TARA-002 compared to Investigator's choice of intravesical chemotherapy

Up to Month 60
Time to disease worsening
Tidsramme: Up to Month 60

Time to disease worsening of intravesical TARA-002 compared to Investigator's choice of intravesical chemotherapy

Up to Month 60

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Faktiske)

29. mai 2026

Primær fullføring (Antatt)

1. april 2028

Studiet fullført (Antatt)

1. november 2032

Datoer for studieregistrering

Først innsendt

13. mars 2026

Først innsendt som oppfylte QC-kriteriene

13. mars 2026

Først lagt ut (Faktiske)

18. mars 2026

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

6. oktober 2026

Siste oppdatering sendt inn som oppfylte QC-kriteriene

5. oktober 2026

Sist bekreftet

1. juni 2026

Mer informasjon

Begreper knyttet til denne studien

Plan for individuelle deltakerdata (IPD)

Planlegger du å dele individuelle deltakerdata (IPD)?

NEI

Legemiddel- og utstyrsinformasjon, studiedokumenter

Studerer et amerikansk FDA-regulert medikamentprodukt

Ja

Studerer et amerikansk FDA-regulert enhetsprodukt

Nei

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

Abonnere